Compare Dover Corp (DOV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Dover Corp trades at $193.04 (market cap $25.92B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Dover Corp is far larger — about 3.4× Spyre Therapeutics Inc. Common Stock's market cap, and Dover Corp pays a 1.09% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 74 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| DOV | SYRE | |
|---|---|---|
Market Cap | $25.92B | $7.52B |
Volume | 807,452 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $233.31 | $108.92 |
52-Week Low | $162.66 | $22.18 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $27.43B | $6.52B |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $193.33, up 1.28% with strong analyst consensus of 19 Buy ratings and no Sell recommendations. The stock shows solid fundamentals with consistent earnings beats, 13.48% net margin, and robust cash flow. Recent acquisitions and product launches position the company for growth, while technical indicators suggest neutral momentum near key resistance at $195.
Outlook remains positive with 67.9% analyst Buy rating and $243.20 price target representing 26% upside. Risks include integration challenges from recent acquisitions and industrial sector volatility. The company's Dividend King status and strong balance sheet provide stability amid market fluctuations.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
